Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Charles River Laboratories, the most common co-covered peer. The tracked stories average 3 original sources each. Kallum Titchmarsh appears in 1 tracked Healthcare story from June 19, 2026.
Last mentioned: Jun 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Charles River Laboratories, the most common co-covered peer. The tracked stories average 3 original sources each. Kallum Titchmarsh appears in 1 tracked Healthcare story from June 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Kallum Titchmarsh. Shared-story counts are live from our verified record — not editorial picks.
Morgan Stanley’s upgrade of Charles River and downgrade of IQVIA signal a shift in healthcare R&D outsourcing. CROs with deep ties to small biotech stands to gain as venture funding rebounds, potentially accelerating drug development timelines and altering cost structures for health systems.
Kallum Titchmarsh is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
